Drug Profile
Bevacizumab biosimilar - Coherus BioSciences
Alternative Names: CHS-5217Latest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator Coherus Biosciences
- Developer Coherus BioSciences
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer